Response to comments by Ruiz-Irastorza et al. on the British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

Caroline Gordon1,2,3, Maame-Boatemaa Amisah-Arthur1, Mary Gayed1,3, Sue Brown4, Ian N. Bruce5,6, David D’Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10,11, Munther Khamashta12,13, Liz Lightstone14, Peter Norton15, Yvonne Norton15, Karen Schreiber16,17, David Isenberg18 for the British Society for Rheumatology Standards, Audit and Guidelines Working Group

1Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
2Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
3Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
4Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, UK
5Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre.
6The Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University Foundation Trust, Manchester, UK
7Louise Coote Lupus Unit, Guy’s Hospital, London, UK
8Laurie Pike Health Centre, Modality Partnership, Birmingham, UK
9Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, UK
10Department of Medicine, University of Cambridge, Cambridge, UK
11Lupus and Vasculitis Unit, Addenbrooke’s Hospital, Cambridge, UK
12Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital London UK
13Division of Women’s Health, King’s College London, UK.
14Section of Renal Medicine and Vascular Inflammation, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London, UK
15LUPUS UK, Romford, Essex, UK
16Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK
17Division of Women’s Health, King’s College London, UK
18Centre for Rheumatology, University College London, London, UK

Correspondence to: Caroline Gordon, Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham Research Laboratories, New Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2WB;

p.c.gordon@bham.ac.uk
Sir,

We are grateful to Guillermo Ruiz-Irastorza and colleagues for their very positive comments (1) about the British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults(2). Regarding their comments suggesting that we might have been more radical regarding the dose and duration of corticosteroids we would like to emphasise that we did state in the main text of the executive summary(3) and in the full guideline(2), as well as in our table in both documents suggesting dosing regimens for active disease and maintenance therapy, that the lowest effective dose should be used at all times.

We are well aware of the toxicity of high dose corticosteroids and that many patients will respond to doses well below 1mg/kg/day for severe flares. However there is considerable variation in dosing required in different patients with various lupus manifestations, particularly if they are already on corticosteroids. If intravenous pulses are not being used for any reason, oral doses of prednisolone or equivalent in the range of up to 0.75-1 mg/kg/day may be required for life-threatening conditions unresponsive to the lower dose such as up to 0.5mg/kg/day as suggested first in the table. We specifically recommend in the main guideline section on severe lupus therapy with corticosteroids(2) that the lower dose oral and intravenous regimens should be used rather than the higher doses that have been used in the past. We never suggested that prednisolone doses greater than 30mg/day were required for any specific indication.

We did not quote the paper by Ruiz-Arruza et al.(4) as it was published in early June 2015, just after we ran our last literature search for corticosteroids and we can only apologise that we did not pick this up later and for any other omissions. However this paper and other reports of corticosteroid regimens used in lupus nephritis mentioned by Ruiz-Irastorza et al.(1) do not address or exclude the need for patients with very severe lung, cardiac, gastrointestinal, haematological and neuro-psychiatric lupus requiring higher dose corticosteroid regimens, particularly as the entry criteria for the study reported by Ruiz-Arruza et al.(4) was a SLEDAI score of only 6 or more.

We did not provide any specific recommendations for tapering corticosteroids in non-renal lupus as there was little evidence for a reliable strategy for all lupus patients when we defined the topics for our literature review. This is certainly a topic worthy of further discussion in
the light of new evidence in a future revision of the guideline and we did emphasise reduction to a safer target dose of $\leq 7.5 \text{ mg/kg/day}$ to avoid complications of corticosteroid therapy so we would not expect patients to be exposed to high doses for long periods of time. In the section on key standards of care at the end of the main guideline we discuss again the importance of using the least amount of corticosteroids possible and the importance of adjusting therapy if treatment is not producing the desired effect within the expected time frame to reduce the risk of accumulation of chronic damage.

REFERENCES


